Cord blood stem cells successfully expanded in Phase 1 of Harvard study

November 8, 2013

A few weeks ago, the Harvard Stem Cell Institute (HSCI) announced promising results in a new approach to improving the success of cord blood stem cell transplants. In HCSI’s human clinical trial, scientists provided stem cell transplants to 12 patients using cord blood stem cells that had been treated with a molecule known as 16-dimethyl prostaglandin E2 (dmPGE2). (Sacramento Bee)